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It is April 25, 1995 . . . Lynn just finished her Strabismus and 
Amblyopia final and thus ' is not able to provide a biographical sketch 
at this very moment, so I will have to improvise. We were both born 
in Honolulu, Hawaii. I was born on June 15, 1970 and Lynn was born 
on February 6, 1966 (I think). We are both products of the Hawaii 
public school system and damn proud of it. 
We both attended the University of Hawaii at Manoa, and acutally 
was enrolled in the same Microbiology, and Human Anatomy and 
Physiology classes and never even knew it. Lynn earned a B.S. in 
mathematics (I think) and worked in the "real world" for a few years. 
I fullfilled my pre-requisite requirements and was excepted into the 
Pacific University College of Optometry, Class of 1995. At this 
time, I received a B.S. in Visual Science (some good this will do me 
if I change my profession). One year later, Lynn entered the Class of 
1996 and was assigned to me as my little sibling. 
Eventually, we decided to do this project together and believe it or 
not, amazingly we're still friends. It's been a very long process and 
we hated every second of it, but here it is--our thesis . . 
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ABSTRACT 
Background: The demand for a milder, yet effective dilation drop 
prompted Allergan to introduce Paremyd™ to the eye care community in 
1993. This study sought to form clinical comparisons between 
Paremyd™ and the standard drug regimen for dilation of 1% 
tropicamide/2.5% phenylephrine. 
Methods: 23 subjects who ranged from 23-29 years of age were 
dilated with 1 drop each of 1% tropicamide and 2.5% phenylephrine in 
the right eye and 1 drop of Paremyd™ in the left eye. Pupil diameter 
and accommodative amplitude (using the push up method) was evaluated 
at 0, 10, 20, 30, 45, 60, 90, 120, 150 and 180 minute intervals while 
intraocular pressures were attained at 0, 30, 60, 120 and 180 minute 
intervals. 
Results: Analysis revealed that Paremyd™ had a slightly less 
mydriatic and cycloplegic effect than the standard drug regimen. There 
was also a difference in efficacy when segregating participants due to 
irides' color with both dilation methods having a greater mydriatic 
effect on non-brown eyed vs. brown eyed subjects. The reverse was 
true when cycloplegic effect was analyzed. 
Conclusions: It is difficult to assess which regimen should be the 
drug or drugs of choice with regard to pupil dilation. Paremyd™ proves 
to be an effective, milder mydriatic agent. Although in brown eyed 
individuals, one drop of Paremyd™ may fall slightly short of the 
desired 7 mm dilated pupil. 
KEYWORDS 
Mydiasis, cycloplegia, accommodative amplitude, intraocular pressure, 
pupillary dilation. 
Introduction 
With the trend toward the increased use of diagnostic and 
therapeutic drugs and the current standard of care in the optometric 
profession1, it is now not so much a question of whether or not a 
dilated fundus evaluation will be integrated into a routine vision 
examination; but rather, which drug or combination of drugs will be the 
most effective and least debilitating for the patient while enhancing 
the view of the internal structures of the eye. In the late 1800s, 
homatropine and cocaine2 were the drugs of choice for observation of 
the fundus. Now almost 200 years later, there are other more suitable 
and less "stimulating" options out on the market. Among the more 
popular of these options is the drug combination of 1.0% tropicamide 
and 2.5% phenylephrine, and Paremyd™ (0.25% tropicamide and 1.0% 
hydroxyamphetamine hydrobromide). 
Tropicamide is a parasympatholytic agent which blocks 
cholinergic stimulation at the muscarinic receptor sites in both the 
ciliary body and the iris sphincter. The anticholinergic activity of this 
agent effectively causes mydriasis and cycloplegia by competing with 
acetylcholine at these effector sites3. The efficacy of tropicamide 
depends somewhat on the concentration and the intent of the 
practitioner (whether it is utilized for the purpose of dilation or to 
inhibit accommodation). It has been proven that there is not a 
significant difference in maximum mydriasis between concentrations 
of 0.25% to 1.0%4 ; however, this consistency between the differing 
concentrations remains untrue when cycloplegia is taken into account. 
It has been shown that there is a direct increase in the dioptric value 
of residual accommodation with a decrease in the concentration of the 
drugs. The maximum mydriatic effect of tropicamide, regardless of 
irides' color, typically occurs within 30 minutes following drug 
instillation, whereas the maximum cycloplegic effect usually is 
evident 30-35 minutes post-instillation. Another possible reaction 
secondary to the use of tropicamide is a slight increase in intraocular 
pressure in patients with open angle glaucoma, although the pressure 
elevation is usually minimal and involves absolutely no risk to the 
patients. 
Phenylephrine and hydroxyamphetamine hydrobromide are both 
sympathomimetic agents which cause contraction of the iris dilator 
muscle. This specificity of action results in mydriasis with little or 
no effect on accommodation. Phenylephrine acts directly as an alpha 
receptor agonist, whereas hydroxyamphetamine follows a more indirect 
approach by stimulating the release of norepinephrine. Both agents 
have been proven to be similar in their efficacy in producing mydriasis, 
with 2.5% phenylephrine requiring 70.2 minutes and 1.0% 
hydroxyamphetamine requiring 64.8 minutes to accomplish maximum 
dilations. It has been speculated that phenylephrine may result in a 
decrease in lOP; while on the other hand, hydroxyamphetamine typically 
has little or no effect on IQP5. 
Methodology 
The study population consisted of 23 volunteers, 5 males and 17 
females, who ranged in age from 23 to 29 years of age. There were 13 
subjects with brown irides and 10 subjects with non-brown irides. All 
subjects were free of ocular and systemic disease, and received 
comprehensive vision examinations from the Pacific University College 
of Optometry Family Vision Center prior to participation in this study. 
Volunteers were excluded from the study for the following reasons: (1) 
contact lens wear during the investigation; (2) allergies to any of the 
components in Ophtheticru, tropicamide, phenylephrine and Paremydru; 
(3) hypertension, diabetes, pregnancy, cardiac or thyroid disease; (4) 
current use of tricyclic antidepressants, beta adrenergic blocking drugs 
or monoamine oxidase inhibitors; (5) corneal disruption or narrow 
anterior chamber angles; (6) a history of angle closure or open angle 
glaucoma; (7) pupillary defects; (8) presbyopia. All subjects read and 
signed a written informed consent prior to entering the study. 
The first pre-instillation test was a pupil screening to assess 
normal direct, consensual and accommodative responses; as well as to 
rule out an afferent pupillary defect. Evaluation was completed under 
dim illumination. Following this initial screening, two baseline pupil 
diameter measurements were taken. 
entopic pupillary diameter technique. 
This was accomplished using an 
Black 2" x 5" poster board with 
pinholes spaced 3 mm to 11 mm apart in 1 mm step increments was 
positioned by the subject in front of the pupil being evaluated. The 
card was placed in front of the participant's eye, with the measurement 
device just clearing their eyelashes. Pupillary diameters were then 
measured by matching the corresponding millimeter separation in 
which the subject reported that the two circles were just touching. 
The pinhole separation thus indicates the pupillary diameter. 
Measurements were taken in standard room illumination and in dim 
illumination with the 810 light shone in the eye not being evaluated (via 
a high powered condensing lens) to provide us with a consensual 
response. This consensual response was used as the indication of the 
degree of inhibition of the pupillary light reflex. The need to be able to 
maintain pupillary dilation unde.r intense illumination, as experienced 
during a 810 examination, mandates the need for ellimination of this 
pupillary light reflex. 
Once this information was collected, monocular accommodative 
amplitudes were measured using the 0.50 M print size on a standard 
Dander's near point card. The participant, wearing their best corrected 
distance prescription, used the push-up technique and was instructed 
to bring the card towards them until the letters of this paragraph 
became too blurry to read. Equal effort was exerted between the two 
eyes and for all further measurements. A corneal health assessment 
and anterior chamber angle estimation using the Van Herick technique 
was completed at this time. The final pre-instillation test was an lOP 
measurement using the Keeler pulsair. Two measurements within three 
mmHg were mandatory for each eye. 
One drop each of Alcaine™ (0.5% proparacaine), 1% tropicamide 
and 2.5% phenylephrine was instilled in the right eye, while one drop 
each of Alcaine™ and Paremyd™ was placed in the left eye. All drops 
were spaced one minute apart, with tropicamide being the first drop 
instilled one minute after the anesthetic was placed in both eyes. 
Phenylephrine and ParemydTM were the final group of drops 
administered. Punctal occlusion was performed after instillation of 
each drop. 
Pupil diameters and accommodative amplitudes were taken 10, 
20, 30, 45, 60, 90, 120, 150 and 180 minutes post instillation, while 
lOPs were taken at the 30, 60, 120 and 180 minute mark. 
RESULTS 
Despite the initial variability in the accommodative abilities 
between the subjects' right and left eyes, there was still a 
statistically significant difference between the 
tropicamide/phenylephrine eye and the Paremyd™ eye at all 
measurement intervals (figure 1-1 ). The maximum cycloplegic effect 
of the tropicamide/phenylephrine combination occurred at 30 minutes 
post-instillation with a residual accommodation of 21.96% of the 
initial amplitude, whereas Paremyd'sTM maximal effect was evident at 
the 45 minute mark with a residual value of 32.22% (figure 1-2). 
Recovery time with ParemydTM showed a 50% recovery value at 
approximately 120 minutes vs. 150-180 minutes for the two drug 
combination. 
However, tropicamide/phenylephrine produced a greater mydriatic 
effect than ParemydTM at each of the measured intervals (figure 1-3). 
There was a 15 minute difference in peak mydriasis between the two 
eyes with the tropicamide/phenylephrine eye, producing a 7.57 mm 
pupil diameter at the 45 minute point and the Paremyd™ eye dilating to 
7.11 mm at the 60 minute mark. 
Intraocular pressure decreased with the use of 
tropicamide/phenylephrine with a 180 minute reading that was 
slightly lower than the pre-instillation value. However, Paremyd's™ 
effect on lOPs was somewhat more inconsistent, resulting in a final 
value 0.12 mmHg higher than the original (figure 1-4). 
When differentiating between irides• color in the study 
population, both drug regimens affect the accommodative performance 
of subjects with brown irides to a greater extent and more rapidly than 
those with non-brown (and hazel) irides (figures 2-1 and 2-2). Upon 
comparison of recovery percentages, the brown eyed subjects recovered 
40.7% of initial accommodative ability at the 180 minute reading when 
tropicamide/phenylephrine was utilized, while with the use of 
Paremyd™, 53.9% of initial amplitude was restored. However, in the 
non-brown eyed subjects, 82.2% of the original value was restored at 
the final measurement with the two drug combination, while only 69.0% 
of the initial amplitude was recovered when Paremyd™ was utilized. 
With regard to pupil dilation, greater drug efficacy is seen on 
non-brown eyed individuals (figures 2-3 and 2-4) with 
tropicamide/phenylephrine reaching a maximum value of 8.10 mm at 45 
minutes post-instillation and Paremyd™ attaining a 7.55 mm dilation 
at 60 minutes. The brown eyed individuals reached a plateau of 
approximately 7.15 mm from 45-90 minutes with the two drug combo 
and 6.77 mm from 45-60 minutes with Paremyd™. 
Intraocular pressures were markedly stable in brown eyed 
subjects with the dilation process raising the lOPs in both conditions; 
however, there was quite a bit of variability among the non-brown eyed 
subjects (figures 2-5 and 2-6) with a 180 minute reading that was 
significantly lower than the initial measurement. Upon comparison of 
their initial and final readings, tropicamide/phenylephrine lowered 
pressures an average of 3 mmHg and ParemydTM decreased values an 
average of 2.5 mmHg. 
DISCUSSION 
Paremyd'sTM claim of being a milder dilation drop seems to be well 
substantiated. The foremost goal of this study was to create an 
environment in which results would be applicable and relevant to the 
optometric community. To provide this realistic situation, the 810 
light and the high plus condensing lens were employed to simulate 
actual pupil responses during a dilated fundus evaluation. With a 7 mm 
pupil diameter as the goal to provide an adequate fundus examination, 
eye care practitioners using 1.0% tropicamide and 2.5% phenylephrine 
can expect to wait 20 minutes for dilation of this magnitude to occur, 
whereas those using ParemydTM would require more than twice the 
amount of time to reach a diameter of this size. The greater 
tropicamide concentration appears to be the factor in the quicker 
dilation of the pupil when comparing the two dilation methods. 
Another true to life method that was employed was the use of 
printed material in measuring the accommodative ability. Although 
this technique may not be quite as precise and "clean.. as other 
unorthodox procedures, this provided the most useful information and 
allowed the application of this data to real life accommodative 
performance. With the assumption that 5 diopters of accommodative 
ability is required to read comfortably at 40 centimeters, patients who 
are dilated with Paremyd™ can expect to resume near work at 60 
minutes following drop instillation; however, those dilated with 
tropicamide/phenylephrine will be debilitated for at least 120 minutes. 
At the 180 minute point, the Paremyd™ eye recovered 60.18% of their 
original amplitude, while the tropicamide/phenylephrine subjects were 
at 54.94% of their initial ability. Once maximum cycloplegia was 
achieved, the drug combo lagged behind approximately 30 minutes with 
regard to accommodative recovery. 
When segregated according to irides' color, the data seems to 
indicate that when the drugs' potential mydriatic effects are 
considered, brown eyes are less susceptible to dilation than non-brown 
eyes. This is contradictory to cycloplegic effects with the darker 
irides being affected quicker and to a greater extent than lighter 
colored irides. However, it remains somewhat suspicious that the 
subjects with non-brown eyes recovered their accommodative ability 
over time at a greater value when tropicamide/phenylephrine was used 
vs. Paremyd™. This may be due to human error on the part of the 
participant or the examiner. Also of special note, there seems to be 
quite a bit of variability of initial accommodative amplitude 
measurements between the two eyes of those with non-brown irides (a 
2.880 difference). However, those with brown irides were much more 
internally consistent (0.51 D difference). This variability could well be 
the cause for the somewhat unexpected finding. 
Figure 1-4 may be somewhat misleading due to the small 
increments utilized to compare the mmHg changes over time. Upon 
precise examination, the variability is not quite as extensive as may 
first appear. It may be of interest to note that the eye in which 
phenylephrine was instilled, which has been considered to have a 
possible decreasing effect on IOP5 , followed suit and supported 
previous speculations. With further investigation, it appears that lOP 
fluctuation over time seems to be influenced by iris color. Could it be 
theorized that the decrease in iris fibers and pigment play a role in 
this variability? Further study is required to form concrete 
conclusions on this matter. 
CONCLUSIONS 
After much analysis, there is still some uncertainty as to which drug 
regimen is the best choice. In all circumstances, it appears that 
Paremyd™ will provide most eye care practitioners with an adequate 
dilation while leaving the patient with enough accommodative ability 
to continue with their daily activities. When comparing the significant 
cycloplegic effect and the rapid onset of tropicamide/phenylephrine vs. 
the relatively milder effect of Paremyd™, patients will most likely not 
be quite as aware of their decreased vision if the latter drug is used. 
If this adverse effect can be minimized, the negativity associated with 
being dilated may be somewhat diminished. Ultimately, the key factor 
is time. Can we, as eye care providers, wait an extra 20 minutes for 
Paremyd™ to dilate those extra-tough dark brown irides? What kind of 
effect will 2 drops of Paremyd™ have on this population? As other 
pertinent questions arise, it still remains evident that in the battle of 
the mydriatic drugs, there is no clear cut winner. 
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8-D OD 3.00 4.00 5.00 5 .00 7 .00 7.00 5.00 6.00 6.00 4.00 
9-D OD 4.00 7 .00 8 .00 8 .50 9 .00 8.50 8 .00 8 .00 7.00 6 .00 
10-D OD 3.00 5 .00 6 .50 7 .00 7 .50 7 .00 7.00 7.50 7.00 7 .00 
11 -D OD 3.00 6 .00 7 .00 7.00 7.00 7.00 7 .00 7.00 7.00 7 .00 
12-D OD 5.00 6.00 6.50 7 .00 7 .00 7 .00 7.00 6.00 6.00 6 .00 
13-D OD 3.50 5.00 7 .50 8.00 8 .50 9.00 9.00 8.50 9.00 8.50 
14-D OD 3.00 8.00 9 .00 9.00 9.00 9.00 9.00 8.00 8.50 8.00 
15-D OD 4.00 4.00 7 .00 8 .00 8 .00 8.00 8 .00 8 .00 7.00 7.00 
16-D OD 3 .00 3.00 6 .00 6 .00 6 .00 6 .00 6 .00 6 .00 6 .00 5.00 
17-D OD 3.00 5 .00 7 .00 7 .00 7.00 7.00 7.00 7.00 7.00 7 .00 
18-D OD 4.00 6.00 7 .00 8 .00 8 .00 8.00 8.00 8.00 7.00 6 .00 
19-D OD 3.00 4.00 7.00 7.00 7.00 7 .00 7.00 6.00 6.00 6.00 
20-D OD 3.00 5.00 7.00 7.00 8.00 7 .50 7.00 7.00 6.50 6.00 
21 -D OD 4.00 8.00 9 .00 9.50 8 .00 8.00 9.50 8.00 9.00 7.00 
22-D OD 3.50 6 .00 8 .00 8 .50 9 .00 8 .50 8.00 8 .00 8 .00 8 .00 
23-D OD 4.00 7 .00 8 .00 8.00 8 .00 7.00 9 .00 7 .50 6.50 7 .00 
24-D OD 
25-D OD 
26-D OD 
27-D OD 
28-D OD 
29-D OD 
30-D OD 
AVERAGES 3.50 5.52 6.98 7.28 7.57 7.41 7.39 7.11 6.91 6.57 
1-D OS 4.00 5.00 5 .00 6 .50 7.00 7.00 7 .00 7.00 6 .50 6 .50 
2-D OS 3.00 3.00 5 .00 6 .00 6 .00 6.50 6.50 6 .00 6 .00 6 .00 
3-D OS 3.00 4.00 6 .00 6.00 7 .00 7 .00 7.00 6.00 7.00 6 .00 
4-D OS 3.50 3.50 3.75 3.50 4.50 4.50 4.50 4.00 4.00 3.50 
5-D OS 3.00 4.00 5.00 6 .00 6 .00 7 .00 7.00 6.00 6.00 6.00 
6-D OS 3.00 4.00 5.00 6 .00 6.00 6.50 6.00 6.00 5.50 6.00 
7-D OS 3.00 4.00 6 .00 6 .00 7.00 7 .00 6.00 7.00 7.00 6.00 
8-D OS 3 .00 4.00 6.00 6 .00 7 .00 6 .00 6.00 6 .00 6 .00 3 .00 
9-D OS 4.00 5 .00 7 .50 8 .00 8 .00 8 .00 7.00 7.00 7 .00 5.00 
10-D OS 3.50 4.50 6.50 7.00 7 .50 6 .50 7 .00 7.50 6.00 6.00 
11 -D OS 3.00 5.00 6.00 7.00 6 .00 7.00 6.00 6.00 6.00 6.00 
12-D OS 4.00 5.00 6 .00 6 .50 7.00 7.00 7.00 6 .00 6.00 6.00 
13-D OS 3.50 5.00 7 .00 _8._00 9.QQ ____ 9 .00 8.00 9 .00 9.00 9.00 
14-D OS 3 .00 5 .00 8 .00 9.00 9 .00 8 .50 8 .50 8.00 7.00 7 .001 
15-D OS 4.00 4.00 7 .00 8 .00 8.00 9.00 8 .50 8 .00 8 .00 8 .001 
16-D OS 4 .00 4.00 6.00 6.00 7.00 6 .00 7.00 7.00 6 .00 6 .00 
17-D OS 3.50 5.00 7 .00 7.00 7.00 7 .00 7.00 7,00 7.00 6.00 
18-D OS 4.00 5 .00 7 .00 7.00 7 .00 8 .00 8.00 7.00 7.00 7 .00 
19-D OS 3 .00 3.00 5 .00 6 .00 6.00 7 .00 5.00 6 .00 5.00 4.00 
20-D OS 3 .00 3.00 5.00 7.00 7.00 7.00 7.00 7 .00 6.50 6.00 
21-D OS 4 .00 4.00 7.00 8 .00 9.00 7.00 8.50 6.50 5.00 6 .00 
22-D OS 3 .50 3.00 4.00 5 .00 6.00 8.00 6.00 5.00 4.00 4 .00 
23-D OS 3 .00 3.00 5.00 7.00 8.00 7.00 7.00 7.00 5.00 6.00 
24-D OS 
25-D OS 
26-D OS 
27-D OS 
28-D OS 
29-D OS 
30-D OS 
AVERAGES 3 .41 4.13 5.90 6.63 7.04 7 . 11 6 .85 6.61 6.20 5.87 
I 
1-AA OD 8 .00 19.50 47.00 47.00 48 .00 48 .00 42.00 34 .50 24.00 20.00 
2-AA OD 5 .00 13 .00 22.00 24 .00 25 .00 21 .00 27.00 12.50 12.00 8 .00 
3-AA OD 5 .00 28 .50 34 .00 39.50 36 .50 27 .00 30.50 26 .00 25 .50 18.50 
4-AA OD 5 .00 11.00 17.50 26 .50 27 .00 27 .00 12 .00 12.00 10.00 10.00 
5-AA OD 10.00 18.00 30.00 39.50 40 .00 34 .00 26 .00 24 .00 20 .50 20 .00 
6-AA OD 5 .00 14.00 25.00 26.00 32.00 38 .00 36 .00 24 .00 22 .00 18.00 
7-AA OD 9.00 23 .00 38 .00 46 .00 41.00 31.00 13.50 13 .00 14.00 12.00 
8-AA OD 10 .50 30.00 32.00 37.00 16.50 16.00 11.00 13.00 13.00 11 .00 
9-AA OD 7 .00 35.50 40.00 46 .50 34.00 16.00 9.50 9 .00 7.50 8 .50 
10-AA OD 6 .00 24.00 30 .00 48.00 50.00 45 .00 33 .00 24.00 13.00 10.00 
11-AA OD 6 .50 16.00 33.50 37.00 42.00 32.00 25.00 16.00 12.00 10 .00 
12-AA OD 9 .00 10.00 14.00 14.00 13 .00 12.00 13.50 8.00 7.00 8 .00 
13-AA OD 7 .50 60.00 60.00 60.00 60.00 60.00 60.00 60 .00 60.00 58 .00 
14-AA OD 7 .00 15.50 21.00 25.50 22 .00 19 .00 11.00 9 .50 9.50 8 .00 
15-AA OD 10 .00 14.00 17 .50 20.00 20 .00 19.00 13.00 14 .50 14.50 13.50 
16-AA OD 6 .00 20 .00 25.00 38.00 39 .00 41.00 25 .00 15 .50 13.00 13 .00 
17-AA OD 9 .00 11.00 27 .00 32 .00 26 .50 24 .00 20.00 15 .50 14.50 11 .00 
18-AA OD 6.00 13.00 18 .50 18 .50 29 .00 22 .00 18 .00 13.50 14.00 10.00 
19-AA OD 6.00 18 .00 39.00 50.00 48.00 44 .00 17.50 13.00 11.00 11.00 
20-AA OD 9 .50 30.00 33.50 65 .50 54 .00 51 .00 25 .50 22 .50 14.00 13 .00 
21-AA OD 19 .00 20.50 44 .00 36.50 15 .50 24 .50 21 .00 16.50 17.00 15 .00 
22-AA OD 7 .00 13.50 15.00 16.00 14.50 13.50 11.50 9.50 10.00 9 .00 
23-AA OD 10 .50 35.00 40 .50 42.50 37.00 38.00 39.00 29.00 19.00 18.50 
24-AA OD 
25-AA OD I 
26-M 00 
27-AA 00 
28-AA 00 
29-AA 00 
30-AA 00 
AVERAGES 7.98 21 .43 30 .61 36.33 33 .50 30.57 23.50 18.91 16.39 14.52 
1-AA OS 6.50 10.00 12.50 18.00 19.00 15.00 17.00 12.50 11.50 9.00 
2-AA OS 6.00 6.00 9.00 13.00 13.00 12.00 14.00 9.50 9 .00 6 .50 
3-AA OS 5.00 14.00 20 .50 23.50 24 .00 21 .00 18 .00 14 .00 15.00 11 .00 
4-AA OS 4.50 5.00 5.00 7.00 9.00 9.00 6 .00 5.00 6.00 4.50 
5-AA OS 11.00 18.00 20.00 22 .50 21.00 19.00 16.00 16.50 13.00 14 .00 
6-AA OS 6.00 10.00 15.00 17.50 22 .00 19.00 18.50 16.00 16.50 14.00 
7-AA OS 9.50 13.50 18.00 18.50 16.50 15.00 11.50 14 .50 12.50 13 .00 
8-AA OS 8.50 16.00 21.00 19.00 11.50 12.50 12 .00 12.00 12.00 10.00 
9-AA OS 5.00 10.00 11.50 13.00 10.50 8 .00 7 .00 7.00 7.50 7 .50 
10-AA OS 7.00 15.00 30.00 26 .00 37.00 23.00 18.00 11.00 9 .00 5.00 
11 -AA OS 7.00 12.00 15.00 18.00 20.00 15.00 14.00 11.00 11.00 10 .00 
12-AA OS 8.00 9.00 10.00 10.00 11 .00 11.00 9.00 8.00 6.50 7.00 
13-AA OS 8.00 46.50 60.00 60.00 60.00 60.00 60 .00 60.00 60.00 46.00 
14-AA OS 6.00 10.00 14.50 16.00 13.50 13 .00 10.00 9 .00 9.00 8.50 
15-AA OS 9.00 20.00 27 .00 31.00 28 .00 22 .00 15 .00 14.00 14.50 13 .50 
16-AA OS 5.50 14.00 25 .00 32.00 33.00 31.00 18 .00 13.50 12.50 12 .00 
17-AA OS 8.00 13.00 19.00 23 .00 21.00 16 .00 19.00 14.50 12.50 11 .00 
18-AA OS 4.00 9.50 18.00 16.00 32.00 31.00 14.50 14.50 13 .50 10.00 
19-AA OS 4.50 7.50 11 .50 13.00 13.50 10 .00 10.00 7.00 9.00 9.00 
20-AA OS 8.50 13.50 13.00 25.00 24.00 21 .00 17.00 13.50 12.00 12 .00 
21-AA OS 10.00 16.00 21 .00 22 .00 19.00 15.00 15.50 15.00 .17.00 22 .00 
22-AA OS 7.00 8 .00 9.00 11 .00 10.00 10.00 10 .00 8.50 10.00 7 .50 
23-AA OS 9.50 23.00 34.00 38 .50 40.50 33.00 37.00 22.00 13.50 9.50 
24-M OS 
25-AA OS 
26-AA OS 
27-AA OS 
28-M OS 
29-AA OS 
30-AA OS 
AVERAGES 7.13 13.89 19.11 21.46 22 .1 3 19.20 16.83 14.28 13.61 11.85 
0 30 60 120 18 0 
1-1 00 12 .00 13.00 13.00 12.00 12 .00 
2-1 00 13 .00 12 .00 13.00 16.00 14.00 
- -- -
3-1 OD 12.00 10.00 14.00 12 .00 12.00 
4-1 OD 12.00 13.00 10.00 14.00 12.00 
5-1 OD 12 .00 11.00 13.00 12.00 12 .00 
6-l OD 13 .00 14.00 14 .00 13.00 13 .00 
7-1 OD 17.00 17 .00 17 .00 17 .00 17 .00 
8-1 OD 15.00 15.00 14 .00 12.00 
9-1 OD 13.00 12.00 13 .00 11.00 14.00 
10-1 OD 20.00 20.00 20.00 15.00 18 .00 
11-1 OD 19.00 24.00 17.00 20.00 16 .00 
12-1 OD 22.00 19.00 19.00 
13-1 OD 15.00 13.00 13.00 16 .00 18 .00 
14-1 OD 15.00 12.00 13.00 11.00 11 .00 
15-1 OD 19.00 21.00 18.00 16.00 16.00 
16-1 OD 23.00 19.00 18.00 18.00 24 .00 
17-1 OD 18.00 13.00 16.00 16.00 18 .00 
18-1 OD 17.00 15.00 14.00 17.00 17.00 
19-1 OD 13 .00 12.00 12 .00 12.00 16 .00 
20-1 OD 15.00 16.00 16.00 15.00 16 .00 
21-1 OD 14.00 14.00 17.00 15.00 15.00 
22-1 OD 13.00 12.00 14.00 12.00 13 .00 
23-1 OD 20.00 20.00 14.00 18 .00 19.00 
24-1 OD 
25-1 OD 
26-1 OD 
27-1 OD 
28-1 OD 
29-1 OD 
30-1 OD 
AVERAGES 15.74 15.09 14.91 14.64 15.23 I 
I 
1-1 OS 12.00 13.00 13.00 11.00 14.00 
2-1 OS 17.00 16.00 20.00 17.00 19 .00 
3-1 OS 12.00 11.00 11.00 16.00 15 .00 I 
4-1 OS 13.00 10 .00 11.00 14.00 12 .00 
5-1 OS 12.00 14.00 14 .00 13.00 12 .00 I 
6-1 OS 12.00 14.00 13.00 13.00 13 .00 I 
7-1 OS 13 .00 17.00 15.00 16.00 18 .00 
8-1 OS 15.00 14.00 14 .00 13.00 
9-1 OS 15.00 11.00 13.00 14.00 14.00 
10-1 OS 17.00 19.00 19 .00 18 .00 22 .00 
11-1 OS 17.00 19.00 19.00 19.00 23.00 
12-1 OS 22.00 23.00 22 .00 
13-1 OS 15.00 13.00 14.00 14.00 15 .00 
14-1 OS 14.00 13.00 12.00 10.00 8 .00 
15-1 OS 20.00 21 .00 18.00 17.00 18 .00 
16-1 OS 26.00 20.00 20.00 18.00 24.00 
-
17-1 OS 19.00 17.00 15.00 15.00 19.00 
18-1 OS 17.00 15.00 16.00 17.00 17.00 
19-1 OS 13.00 13.00 13.00 14.00 12.00 
20-1 OS 16.00 13.00 18.00 15.00 15 .00 
21-1 OS 14.00 12.00 16.00 13.00 15.00 
22-1 OS 12.00 15.00 17.00 15.00 14.00 
23-1 OS 18.00 17.00 18.00 19.00 16.00 
24-1 OS 
25-1 OS 
26-1 OS 
27-1 OS 
28-1 OS 
29-1 OS 
30-1 OS 
AVERAGES 15.70 15.27 15.70 15.09 15.82 
Number of Subjects 23 22 
PUPIL DIAMETER (mm) 0 1 0 20 30 45 60 90 120 150 180 
TROPICAMIDE/PHENYI.EPHRINE 3.50 5.52 6.98 7.28 7.57 7.41 7.39 7.11 6.91 6.57 
PAREMYD 3.41 4.13 5.90 6.63 7.04 7 .11 6.85 6.61 6.20 5.87 
ACCOMMODATIVE AMPLITUDE (D) 0 1 0 20 30 45 60 90 120 150 180 
TROPICAMIDE/PHENYLEPHRINE 12.53 4.67 3.27 2.75 2.99 3.27 4.26 5.29 6.10 6.89 
PAREMYD 14.02 7.20 5.23 4.66 4.52 5.21 5.94 7.00 7.35 8.44 
lOPs (mmHg) 0 30 60 120 180 
TROPICAMIDE/PHENYLEPHRINE 15.74 15.09 14.91 14.64 15.23 
PAREMYD 15.70 15.27 15.70 15.09 15.82 
%RESIDUAL AMPLITUDE 0 10 20 30 45 60 90 120 150 180 
TROPICAMIDE/PHENYLEPHRINE 100.00 37.22 26.07 21.96 23 .82 26.10 33.95 42.18 48.67 54.94 
PAREMYD 100.00 51.33 37.32 33.23 32 .22 37.15 42.38 49.92 52.40 60.18 
PUPIL DIAM-TROPIC/PHENYL 0 1 0 20 30 45 60 90 120 150 180 
BROINN 3.35 5.12 6.62 6.92 7.15 7.12 7.19 6.88 6.65 6.54 
NON-BROWN AND HAZEL 3.70 6.05 7.45 7.75 8 .10 7.80 7.65 7.40 7.25 6.60 
PUPIL DIAM-PAREMYD 0 10 20 30 45 60 90 120 150 180 
BROINN 3.31 4.00 5.56 6.38 6.77 6.77 6.54 6.58 6.12 5.92 
NON-BROWN AND HAZEL 3.55 4.30 6.35 6.95 7.40 7.55 7.25 6.65 6.30 5.80 
- --- ----
AA-TROPICAMIDE 0 10 20 30 45 60 90 120 150 180 
BROWN 14.61 4 .33 3.00 2.43 2.48 2.62 3.31 4.27 5.20 5.94 
NON-BROWN AND HAZEL 10.58 5.18 3.70 3.34 4.07 4.83 6.76 7.66 7.87 8.70 
AA-PAREMYD 0 10 20 30 45 60 90 120 150 180 
BROWN 15.12 6.86 4.82 4.13 3.87 4.56 4.88 6.21 6.58 8.15 
NON-BROWN AND HAZEL 12.82 7.69 5.88 5 .59 5.78 6.39 8.30 8.40 8.66 8.85 
lOPS-TROPIC/PHENYL 0 30 60 120 180 
BROWN 15.77 15.31 14.62 15.15 16.00 
NON-BROWN AND HAZEL 15.70 13.30 15.30 12.50 12.70 
IOPS-PAREMYD 0 30 60 120 180 
BROWN 15.92 15.00 15.69 15.62 16.85 
NON-BROWN AND HAZEL 15.40 14.10 15.70 12.90 12.90 
